[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100611443":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":30,"centralContacts":35,"locations":40,"responsibleParty":44,"collaborators":48,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":40,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":40,"maxAge":40,"enrollmentInfo":59,"targetDuration":40,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":40,"overallStatus":108,"whyStopped":40,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":40},{"fullName":5,"class":6},"Dartmouth-Hitchcock Medical Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Hyperbaric oxygen treated group","EXPERIMENTAL","This individuals will be receiving hyperbaric oxygen treatment for the condition listed in the conditions section. Patients come daily for the treatment and receive hyperbaric oxygen at 2.0-2.4 atmospheres absolute for 90 minutes at the treatment pressure.",[13,14],"Device: Hyperbaric oxygen treatment (HBOT)","Drug: 100% Oxygen",[16,23],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DEVICE","Hyperbaric oxygen treatment (HBOT)","Hyperbaric oxygen refers to oxygen given at pressures higher than atmospheric pressure (higher than 1.4 ATA) in pressurized chamber.",[9],[22],"HBO2",{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","100% Oxygen","Receiving 100% oxygen as part of HBOT",[9],[29],"O2",[31],{"name":32,"affiliation":33,"role":34},"Jay Buckey","Dartmouth-Hichcock Medical Center","PRINCIPAL_INVESTIGATOR",[36,42],{"name":37,"role":38,"phone":39,"phoneExt":40,"email":41},"Samantha Leigh","CONTACT","540-819-5715",null,"samantha.m.leigh@dartmouth.edu",{"name":32,"role":38,"phone":40,"phoneExt":40,"email":43},"Jay.C.Buckey.Jr@dartmouth.edu",{"type":45,"investigatorFullName":46,"investigatorTitle":47,"investigatorAffiliation":5,"oldNameTitle":40,"oldOrganization":40},"SPONSOR_INVESTIGATOR","Jay C. Buckey Jr.","Principal Investigator",[49],{"name":50,"class":6},"Dartmouth College","100611443","phase-4-outcomes-from-hyperbaric-oxygen-hbo2-treatment-for-emerging-indications-100611443",false,"NCT07240649","Outcomes From Hyperbaric Oxygen (HBO2) Treatment for Emerging Indications","Emerging Indications for Hyperbaric Oxygen Treatment","Inclusion Criteria:\n\n* Patients referred for HBOT with an emerging indication\n\nExclusion Criteria:\n\n* Contraindication to hyperbaric oxygen treatment (untreated seizures, pneumothorax, significant pulmonary airspace pathology that might lead to pulmonary barotrauma, unmanageable confinement anxiety, chronic obstructive pulmonary disease with CO2 retention)\n* Pregnant persons","ALL",{"count":60,"type":61},100,"ESTIMATED","INTERVENTIONAL",[64],"PHASE4","This study will evaluate the effectiveness of hyperbaric oxygen therapy (HBOT) on treating emerging indications (i.e., conditions that have shown to potentially benefit from HBOT) using the Multicenter Registry for Hyperbaric Oxygen Treatment. The study team aims to collect ongoing data on how well HBOT treats these emerging indications, and to add these data to the growing HBO Registry. The research team hypothesizes that HBOT will result in improvements of the condition of the various emerging indications.",[67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107],"Post-COVID-19 Condition","Ulcerative Colitis","Crohn Disease","Calciphylaxis","Frostbite","Acute COVID-19","Pyoderma Gangrenosum","Pterygium","Hypospadias","Head Trauma","Pneumatosis Intestinalis","Ischemic Bowel","Raynaud Syndrome","Malignant Otitis Externa","Nonarteritic Anterior Ischemic Optic Neuropathy","Central Retinal Vein Occlusion","Femoral Head Necrosis","Invasive Fungal Infection","Chronic Anal Fissure","Vasculitic Ulcer","Graft-vs-Host Disease","Decubitus Ulcer","Greater Trochanteric Pain Syndrome","Rectovaginal Fistula","Pouchitis","Tinnitus","Clostridium Enterocolitis","Branch Retinal Artery Occlusion","Axonotmesis","Multiple Sclerosis","Inclusion Body Myositis","Epidermolysis Bullosa (EB)","Osteonecrosis","Ulcer Ischemic","Avascular Necrosis of Bone","Prosthesis Related Infections","Facial Filler Injections","Cystitis Chronic","Ligament Injury","Anastomosis, Leaking","Cartilage Injury","NOT_YET_RECRUITING","2026-05-01",{"date":111,"type":112},"2026-05-05","ACTUAL",{"date":114,"type":61},"2026-08",{"date":116,"type":61},"2035-12",{"name":46,"class":6}]